Chimeric antigen receptor T (CAR-T) cell therapy targeting CLL1 has been considered a potent weapon for patients with acute myeloid leukemia (AML). This study aims to evaluate the efficacy and toxicity of CLL1 CAR-T cell therapy in a larger cohort, with particular attention to cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Among the 32 patients assessed for efficacy, complete remission occurred in 71.88% (23/32) of cases and undetectable minimal residual disease in 14 patients. The CRS developed in all patients, with 8 individuals experiencing ICANS. Severe CRS and ICANS were observed in 11 and 2 patients, respectively. Furthermore, the Endothelial Activation and Stress Index (EASIX) and its derivatives measured before and after CLL1 CAR-T cell infusion were employed for predicting the severe complications. Significant differences were observed in EASIX scores on the day before lymphodepletion (Day BL, P = 0.023), -1 (P < 0.001), +1 (P < 0.001), and +3(P = 0.014); sEASIX scores on Day BL (P = 0.007), -1 (P < 0.001), +1 (P < 0.001), and +3 (P < 0.001); and mEASIX score on Day -1 (P = 0.004) between patients with mild and severe CRS/ICANS. Additionally, there was a significant difference in mEASIX scores between responders and non-responders on Day BL (P = 0.004) and Day -1 (P = 0.044). Our findings indicate that pre- and post-infusion assessments of EASIX/mEASIX/sEASIX scores serve as reliable prognostic indicators for severe CRS/ICANS and treatment response following CLL1 CAR-T cell therapy, which can assist physicians in implementing preemptive treatment strategies for potential severe complications and screening patients who are suitable candidates for CLL1 CAR-T cell therapy. EASIX/mEASIX/sEASIX scores serve as reliable prognostic indicators for severe CRS/ICANS following CLL1 CAR-T cell therapy. The preinfusion mEASIX scores of CLL1 CAR-T cells can effectively predict treatment response.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00277-024-05617-y | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Modified CD15/CD16-CLL1 inhibitory CAR-T cells for mitigating granulocytopenia toxicities in the treatment of acute myeloid leukemia.
Transl Oncol
December 2024
Department of Hematology, Tianjin First Central Hospital, Tianjin 300380, China. Electronic address:
CLL1 Chimeric antigen receptor T-cell (CAR-T) therapy, as a promising immunotherapeutic approach, has demonstrated its potential to enhance the prognosis of patients diagnosed with acute myeloid leukemia (AML). However, due to the overexpression of CLL1 on neutrophils, CAR-T cells not only eliminated tumor cells but also eradicated neutrophils simultaneously, resulting in severe granulocytopenia and subsequent infections. Considering the distinct expression levels of CD15/CD16 on neutrophils and AML blasts, we have devised novel modified CD15 /CD16-CLL1 iCAR structures incorporating diverse inhibitory elements.
View Article and Find Full Text PDFCAR T-cell therapy in acute myeloid leukemia.
Saudi Med J
October 2024
From the Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Shaqra University, Shaqra, Kingdom of Saudi Arabia.
Article Synopsis
- Acute myeloid leukemia (AML) is a serious blood cancer affecting myeloid progenitor cells, with patients facing poor outcomes when the disease relapses or resists treatment.
- Chimeric antigen receptor (CAR) T-cell therapy is being explored as a potential new treatment, with early clinical trials showing promising results targeting specific AML markers like CD33, CD123, and CLL-1.
- However, challenges remain due to the variability of AML and the risk of harmful effects on healthy cells, highlighting the need for further research and improvements in CAR T-cell technology.
Efficacy and safety of CAR-T therapy targeting CLL1 in patients with extramedullary diseases of acute myeloid leukemia.
J Transl Med
October 2024
Department of Hematology, Tianjin First Central Hospital, No.2 Baoshanxi Rd, Xiqing District, Tianjin, 300380, China.
Article Synopsis
- About 10-20% of people with acute myeloid leukemia (AML) also have problems called extramedullary diseases (EMDs), which make their treatment a bit different.
- In a study with 47 patients, results showed that those without EMDs had a better chance of complete remission (getting better) compared to those with EMDs after receiving a special treatment called CLL1 CAR-T therapy.
- Overall, while people with EMDs had similar side effects and CAR-T cell responses as those without EMDs, their recovery and survival were slightly shorter, but the differences weren't big enough to be statistically important.
Article Synopsis
- * A 73-year-old patient with refractory AML benefitted from a new treatment combining CLL1 CAR-T therapy and hematopoietic stem cell transplantation (allo-HSCT), achieving complete remission with minor residual disease.
- * Despite experiencing some side effects like cytokine release syndrome and infections post-transplant, the combined treatment approach proved effective and safe, highlighting its potential for improving outcomes for elderly patients with AML.
Advances in pathogenesis research and challenges in treatment development for acute myeloid leukemia.
Int J Hematol
October 2024
Department of Hematology, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-Ku, Tokyo, 113-8603, Japan.
Article Synopsis
- Acute myeloid leukemia (AML) arises from genetic changes in hematopoietic stem cells that evolve into leukemia stem cells (LSCs), with new mutations identified as key to its development.
- Recent findings classify AML based on inherited mutations, like those in DDX41 and CEBPA, which lead to disease progression and demonstrate unique metabolic regulation in LSCs that contributes to drug resistance.
- Targeted therapies have shown promise, but resistance remains; CAR-T cell therapy is a developing option, especially for specific targets, offering hope for improved treatment outcomes in AML.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!